-
Dec 5, 2024 | 
cancernetwork.com | Brian Wolpin
As artificial intelligence (AI) continues to develop, there is potential that it will be able to access the largely digital medical record database and identify patterns for assessing pancreatic cancer risk that humans are unable to see, according to Brian M. Wolpin, MD, MPH. Wolpin, director of the Gastrointestinal Cancer Center and co-director of the Pancreas and Biliary Tumor Center, and Robert T. and Judith B.
-
Dec 4, 2024 | 
cancernetwork.com | Brian Wolpin
There is a lot going on in the field of pancreatic cancer risk assessment, particularly around genetics and altered metabolism, according to Brian Wolpin, MD, MPH, director of the Gastrointestinal Cancer Center and co-director of the Pancreas and Biliary Tumor Center, and Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School.
-
Dec 3, 2024 | 
cancernetwork.com | Brian Wolpin
According to Brian M. Wolpin, MD, MPH, pancreatic cancer screening is not done often despite its high lethality because of how rare it is. Instead, screening is concentrated among a few subgroups of patients who are suspected to be at higher risk. Wolpin, director of the Gastrointestinal Cancer Center and co-director of the Pancreas and Biliary Tumor Center, and Robert T. and Judith B.
-
Nov 12, 2024 | 
nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more
Correction to: Nature https://doi.org/10.1038/s41586-024-07379-z Published online 8 April 2024In the version of the article initially published, in the Data availability section, the GEO accession number was incorrect and has now been amended to GSE252002 in the HTML and PDF version of the article.
-
Aug 18, 2024 | 
nature.com | Konstantine Tchourine |Keene L. Abbott |Florian Gourgue |Brian T. Do |Tenzin Kunchok |Allison Lau | +9 more
AbstractMetastases arise from subsets of cancer cells that disseminate from the primary tumour1,2. The ability of cancer cells to thrive in a new tissue site is influenced by genetic and epigenetic changes that are important for disease initiation and progression, but these factors alone do not predict if and where cancers metastasize3,4. Specific cancer types metastasize to consistent subsets of tissues, suggesting that primary tumour-associated factors influence where cancers can grow.
-
Apr 8, 2024 | 
nature.com | Alvaro Curiel-Garcia |Margo I Orlen |Clint A. Stalnecker |Julien Dilly |Marie C. Hasselluhn |Stephanie Chang | +16 more
AbstractBroad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations1,2. RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants (RAS(ON) multi-selective)3.
-
Jan 24, 2024 | 
healio.com | Matthew Shinkle |Mindy Valcarcel |Brian Wolpin
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:Recent weight loss correlated with increased cancer risk within the next 12 months. Most common form of cancer among individuals at risk are those of the upper gastrointestinal tract.
-
Dec 11, 2023 | 
nature.com | Carter Grochala |Jennifer L. Guerriero |Gerburg Wulf |Brian Wolpin |Ben Z. Stanger |Andrew J. Aguirre | +1 more
Retraction to: Nature Communications https://doi.org/10.1038/s41467-023-37096-6, published online 13 March 2023RETRACTION NOTEThe Editors retracted this article because of concerns regarding a number of figures presented in this work. These concerns call into question the integrity of the data and the article’s overall scientific soundness.
-
May 8, 2023 | 
nature.com | Davide Placido |Chunlei Zheng |Amalie D. Haue |Piotr Chmura |Renato Umeton |Debora S. Marks | +5 more
AbstractPancreatic cancer is an aggressive disease that typically presents late with poor outcomes, indicating a pronounced need for early detection. In this study, we applied artificial intelligence methods to clinical data from 6 million patients (24,000 pancreatic cancer cases) in Denmark (Danish National Patient Registry (DNPR)) and from 3 million patients (3,900 cases) in the United States (US Veterans Affairs (US-VA)).
-
Mar 13, 2023 | 
nature.com | Jennifer L. Guerriero |Gerburg Wulf |Brian Wolpin |Ben Z. Stanger |Andrew J. Aguirre |Alan D. D’Andrea | +1 more
AbstractRecently developed inhibitors of polymerase theta (POLθ) have demonstrated synthetic lethality in BRCA-deficient tumor models. To examine the contribution of the immune microenvironment to antitumor efficacy, we characterized the effects of POLθ inhibition in immunocompetent models of BRCA1-deficient triple-negative breast cancer (TNBC) or BRCA2-deficient pancreatic ductal adenocarcinoma (PDAC).
